Pfizer Sues Metsera and Novo Nordisk Over Breach of Merger Agreement
Pfizer files lawsuit against Metsera, its board, and Novo Nordisk for breaching a merger agreement, claiming illegal interference and regulatory risks in Novo Nordisk’s proposal.
/ 25 items
#PFE↓
Novo Nordisk Makes $9 Billion Bid for Metsera, Topping Pfizer's Offer
Novo Nordisk offers $77.75/share for Metsera in $9B deal, beating Pfizer's bid. Two-step structure includes immediate $56.50 dividend + milestone payments.
Novo Nordisk Challenges Pfizer's $4.9B Deal for Obesity Startup Metsera
Novo Nordisk makes higher bid for Metsera to outbid Pfizer's $4.9B deal. Learn why this obesity drug startup is sparking a bidding war between pharmaceutical giants.
Ideaya Biosciences Stock Jumps on Promising Eye Cancer Treatment Results
Ideaya Biosciences shares rise after reporting breakthrough survival data for rare eye cancer treatment combining darovasertib with Pfizer's Xalkori in clinical trial.
Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
AstraZeneca Secures Tariff Relief by Pledging Deep Drug Discounts and $50 Billion U.S. Investment
AstraZeneca joins Pfizer in a landmark agreement with the Trump administration, promising "most-favored nation" drug prices, direct-to-consumer sales up to 80% off list price, and a massive investment in U.S. manufacturing in exchange for a three-year tariff exemption.